EXAS Stock Overview
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EXAS from our risk checks.
Exact Sciences Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$65.66 |
52 Week High | US$100.77 |
52 Week Low | US$43.90 |
Beta | 1.46 |
1 Month Change | -2.03% |
3 Month Change | -20.60% |
1 Year Change | 44.15% |
3 Year Change | -51.31% |
5 Year Change | -5.59% |
Change since IPO | 345.15% |
Recent News & Updates
Recent updates
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued
Jan 10Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?
Oct 31Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans
Oct 13Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely
Aug 15Exact Sciences GAAP EPS of -$0.94 beats by $0.14, revenue of $521.64M beats by $25.5M
Aug 02Exact Sciences Won't Likely Escape Consolidation In The Industry
May 25Exact Sciences: Sell-Off Provides An Opportunity To Buy At A Reasonable Valuation
May 14A First Take On Exact Sciences
Feb 16Exact Sciences Is A Pass Based On Its Intrinsic Value
Dec 10Exact Sciences: On Point In A Bearish Market
Sep 22Making Sense Of The Possible Merger Between Exact Sciences And Invitae
Aug 14Cathie Wood’s ARK ETF raises stake in Exact Sciences
Jun 01Exact Sciences Corporation 2021 Q1 - Results - Earnings Call Presentation
May 05Exact Sciences: New Acqusitions Aim To Unlock Strategic Value
Apr 26Shareholder Returns
EXAS | US Biotechs | US Market | |
---|---|---|---|
7D | -0.2% | 3.8% | 0.9% |
1Y | 44.1% | -5.8% | 13.6% |
Return vs Industry: EXAS exceeded the US Biotechs industry which returned -5.8% over the past year.
Return vs Market: EXAS exceeded the US Market which returned 13.6% over the past year.
Price Volatility
EXAS volatility | |
---|---|
EXAS Average Weekly Movement | 6.5% |
Biotechs Industry Average Movement | 11.4% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 15.6% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: EXAS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: EXAS's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 6,350 | Kevin Conroy | https://www.exactsciences.com |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Exact Sciences Corporation Fundamentals Summary
EXAS fundamental statistics | |
---|---|
Market Cap | US$12.12b |
Earnings (TTM) | -US$282.13m |
Revenue (TTM) | US$2.41b |
4.9x
P/S Ratio-42.1x
P/E RatioIs EXAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EXAS income statement (TTM) | |
---|---|
Revenue | US$2.41b |
Cost of Revenue | US$629.54m |
Gross Profit | US$1.78b |
Other Expenses | US$2.06b |
Earnings | -US$282.13m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.56 |
Gross Margin | 73.83% |
Net Profit Margin | -11.73% |
Debt/Equity Ratio | 75.7% |
How did EXAS perform over the long term?
See historical performance and comparison